Lanzor

Lansoprazole, the active ingredient in Lanzor, is a proton pump inhibitor presented as an oral tablet for oral use. It suppresses gastric acid secretion and is indicated for the treatment of gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease and Helicobacter pylori eradication therapy in adult patients, and helps heal related mucosal damage.

GNH USA supplies Lanzor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lanzor (lansoprazole) is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders.

- Gastroesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal healing and prevents further erosion. - Peptic ulcer disease: promotes ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication (as part of combination therapy): enhances eradication rates by suppressing acid production.

Lansoprazole may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate headache. - Diarrhea: loose stools. - Nausea: occasional queasiness. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rare but potentially life‑threatening. - Clostridioides difficile infection: rare severe colitis. - Low magnesium levels (hypomagnesemia): may cause muscle cramps or cardiac arrhythmia.

When prescribing lansoprazole, several precautions should be considered to ensure safe use. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Evaluate for osteoporosis risk: long‑term therapy may increase fracture risk, especially in elderly patients. - Monitor magnesium levels: prolonged use can lead to hypomagnesemia; check periodically. - Use with caution in hepatic impairment: drug metabolism may be altered. - Avoid abrupt discontinuation: tapering may be required to prevent rebound acid hypersecretion. - Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lansoprazole can interact with several medicines, affecting their absorption or metabolism.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption; avoid co‑administration. - Atazanavir: decreased antiviral exposure; avoid concurrent use. - Clopidogrel: reduced antiplatelet effect; avoid combination.

Moderate Interactions (Monitor Closely): - Warfarin: possible increased INR; monitor coagulation. - Digoxin: increased serum levels; monitor for toxicity. - Methotrexate: reduced renal clearance; monitor levels. - Iron supplements: decreased iron absorption; separate dosing by at least 2 hours.